63 related articles for article (PubMed ID: 38770169)
1. Identification of a Macrophage marker gene signature to evaluate immune infiltration and therapeutic response in hepatocellular carcinoma.
Li T; Xu X; Guo M; Guo J; Nakayama K; Ren Z; Zhang L
Heliyon; 2024 Jun; 10(11):e31881. PubMed ID: 38845876
[TBL] [Abstract][Full Text] [Related]
2. Potential applications of dual haptoglobin expression in the reclassification and treatment of hepatocellular carcinoma.
Liu L; Hao S; Gou S; Tang X; Zhang Y; Cai D; Xiao M; Zhang X; Zhang D; Shen J; Li Y; Chen Y; Zhao Y; Deng S; Wu X; Li M; Zhang Z; Xiao Z; Du F
Transl Res; 2024 May; 272():19-40. PubMed ID: 38815898
[TBL] [Abstract][Full Text] [Related]
3. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing to Identify an Immunogenic Cell Death-Related 5-Gene Prognostic Signature in Hepatocellular Carcinoma.
Peng L; Xu S; Xu JL
J Hepatocell Carcinoma; 2024; 11():879-900. PubMed ID: 38770169
[TBL] [Abstract][Full Text] [Related]
4. estimateR: an R package to estimate and monitor the effective reproductive number.
Scire J; Huisman JS; Grosu A; Angst DC; Lison A; Li J; Maathuis MH; Bonhoeffer S; Stadler T
BMC Bioinformatics; 2023 Aug; 24(1):310. PubMed ID: 37568078
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma.
Zhou C; Yang ZF; Sun BY; Yi Y; Wang Z; Zhou J; Fan J; Gan W; Ren N; Qiu SJ
J Hepatocell Carcinoma; 2023; 10():697-712. PubMed ID: 37138764
[TBL] [Abstract][Full Text] [Related]
6. Belantamab mafodotin induces immunogenic cell death within 24 h post-administration in newly diagnosed multiple myeloma patients.
Kostopoulos IV; Kakalis A; Birmpilis A; Angelis N; Orologas-Stavrou N; Rousakis P; Panteli C; Gavriatopoulou M; Kastritis E; Dimopoulos MA; Tsitsilonis O; Terpos E
Am J Hematol; 2023 Mar; 98(3):E65-E67. PubMed ID: 36565455
[No Abstract] [Full Text] [Related]
7. Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer.
Ma L; Heinrich S; Wang L; Keggenhoff FL; Khatib S; Forgues M; Kelly M; Hewitt SM; Saif A; Hernandez JM; Mabry D; Kloeckner R; Greten TF; Chaisaingmongkol J; Ruchirawat M; Marquardt JU; Wang XW
Nat Commun; 2022 Dec; 13(1):7533. PubMed ID: 36476645
[TBL] [Abstract][Full Text] [Related]
8. PDIA3 as a potential bridge between immunogenic cell death and autoreactivity.
Pol JG; Plantureux C; Pérez-Lanzón M; Kroemer G
Oncoimmunology; 2022; 11(1):2130558. PubMed ID: 36211809
[No Abstract] [Full Text] [Related]
9. The immunosuppressive tumor microenvironment in hepatocellular carcinoma-current situation and outlook.
Zhou Z; Hu Y; Wu Y; Qi Q; Wang J; Chen L; Wang F
Mol Immunol; 2022 Nov; 151():218-230. PubMed ID: 36179604
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma.
Xu L; Yang H; Yan M; Li W
Clin Exp Med; 2023 Oct; 23(6):2065-2083. PubMed ID: 36169759
[TBL] [Abstract][Full Text] [Related]
11. Hepatocellular carcinoma.
Vogel A; Meyer T; Sapisochin G; Salem R; Saborowski A
Lancet; 2022 Oct; 400(10360):1345-1362. PubMed ID: 36084663
[TBL] [Abstract][Full Text] [Related]
12. An Overview on Immunogenic Cell Death in Cancer Biology and Therapy.
Rodrigues MC; Morais JAV; Ganassin R; Oliveira GRT; Costa FC; Morais AAC; Silveira AP; Silva VCM; Longo JPF; Muehlmann LA
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015189
[TBL] [Abstract][Full Text] [Related]
13. ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2.
Gustavsson EK; Zhang D; Reynolds RH; Garcia-Ruiz S; Ryten M
Bioinformatics; 2022 Aug; 38(15):3844-3846. PubMed ID: 35751589
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis.
Li Y; Song Z; Han Q; Zhao H; Pan Z; Lei Z; Zhang J
Mol Oncol; 2022 Aug; 16(15):2861-2880. PubMed ID: 35665592
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.
Li Z; Lai X; Fu S; Ren L; Cai H; Zhang H; Gu Z; Ma X; Luo K
Adv Sci (Weinh); 2022 Aug; 9(22):e2201734. PubMed ID: 35652198
[TBL] [Abstract][Full Text] [Related]
16. Glycosylated Cathepsin V Serves as a Prognostic Marker in Lung Cancer.
Yang L; Zeng Q; Deng Y; Qiu Y; Yao W; Liao Y
Front Oncol; 2022; 12():876245. PubMed ID: 35494076
[TBL] [Abstract][Full Text] [Related]
17. CTSV (cathepsin V) promotes bladder cancer progression by increasing NF-κB activity.
Xia Y; Ge M; Xia L; Shan G; Qian H
Bioengineered; 2022 Apr; 13(4):10180-10190. PubMed ID: 35443863
[TBL] [Abstract][Full Text] [Related]
18. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
Su GL; Altayar O; O'Shea R; Shah R; Estfan B; Wenzell C; Sultan S; Falck-Ytter Y
Gastroenterology; 2022 Mar; 162(3):920-934. PubMed ID: 35210014
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
